UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

Annals of oncology, 2017-06, Vol.28 (6), p.1260-1267

2017

Volltextzugriff (PDF)

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

Annals of oncology, 2009-09, Vol.20 (9), p.1499-1504

2009

Volltextzugriff (PDF)

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

Breast (Edinburgh), 2020-12, Vol.54, p.278-285

2020

Volltextzugriff (PDF)

Clinical trial design in biosimilar drug development

Investigational new drugs, 2013-04, Vol.31 (2), p.479-487

2013

Volltextzugriff (PDF)

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.101-107

2013

Volltextzugriff (PDF)

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

Annals of oncology, 2012-08, Vol.23 (8), p.2103-2108

2012

Volltextzugriff (PDF)

An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer

Urologic oncology, 2021-12, Vol.39 (12), p.834.e1-834.e7

2021

Volltextzugriff (PDF)

A Prospective Time and Motion Analysis Comparing Intravenous (IV) Vesus Subcutaneous (SC) Bortezomib in Patients with Multiple Myeloma (MM)

Value in health, 2013-11, Vol.16 (7), p.A427-A427

2013

Volltextzugriff (PDF)

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting

Current oncology (Toronto), 2012-12, Vol.19 (6), p.e414-421

2012

Volltextzugriff (PDF)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis

Journal of oncology pharmacy practice, 2019-09, Vol.25 (6), p.1425-1433

2019

Volltextzugriff (PDF)

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

ClinicoEconomics and outcomes research, 2018-01, Vol.10, p.139-154

2018

Volltextzugriff (PDF)

PSY4 Lenalidomide or Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma (MM): A Comparative Effectiveness Analysis Using Indirect Statistical Techniques

Value in health, 2012-11, Vol.15 (7), p.A508-A509

2012

Volltextzugriff (PDF)

PCN6 Lenalidomide Versus Bortezomib for Treatment of Relapsed/Refractory Multiple Myeloma (MM): A Number Needed to Treat (NNT) Analysis

Value in health, 2012-11, Vol.15 (7), p.A654-A654

2012

Volltextzugriff (PDF)

3602 POSTER The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Castration-Resistant Prostate Cancer (CRPC)

European journal of cancer (1990), 2011, Vol.47, p.S259-S259

2011

Volltextzugriff (PDF)

3603 POSTER The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Patients With Other Solid Tumours or Multiple Myeloma

European journal of cancer (1990), 2011, Vol.47, p.S259-S260

2011

Volltextzugriff (PDF)

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer

Breast cancer research and treatment, 2016, Vol.155 (1), p.77-84

2016

Volltextzugriff (PDF)

A Comparison of Toxicity and Supportive Care Use Between Four Cytotoxic Agents Used in the Management of Metastatic Breast Cancer (MBC)

Value in health, 2014-05, Vol.17 (3), p.A70-A70

2014

Volltextzugriff (PDF)

1590 Patient-related factors in determining the emetic risk potential for patients undergoing chemotherapy: An evaluation of predictive models for the development of a risk assessment tool

European journal of cancer (1990), 2015-09, Vol.51, p.S234-S234

2015

Volltextzugriff (PDF)

PCN92 The Lifecycle Value of Oncology Medicines

Value in health, 2012-06, Vol.15 (4), p.A224-A224

2012

Volltextzugriff (PDF)

PCN83 Novel Targeted Drug Therapies in the Cancer Setting: A Descriptive Comparison of Efficacy and Cost

Value in health, 2012-06, Vol.15 (4), p.A222-A222

2012

Volltextzugriff (PDF)

PCN50 A Pilot Assessment to Determine Cost of Apheresis Treatment

Value in health, 2012-06, Vol.15 (4), p.A216-A216

2012

Volltextzugriff (PDF)

What is a new drug worth? An innovative model for performance-based pricing

European journal of cancer care, 2015-05, Vol.24 (3), p.313-320

2015

Volltextzugriff (PDF)

Small Molecule Targeted Therapies for the Second Line Treatment of Metastatic Renal Cell Carcinoma (mRCC): A Systematic Review and Indirect Comparison of Safety and Efficacy

Value in health, 2013-11, Vol.16 (7), p.A394-A394

2013

Volltextzugriff (PDF)

Long-Acting Muscarinic Antagonists (Lama) In Chronic Obstructive Pulmonary Disease (Copd): A Rare Events Meta Analysis Of Clinically Relevant Adverse Events

Value in health, 2014-05, Vol.17 (3), p.A172-A172

2014

Volltextzugriff (PDF)

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

Journal of oncology pharmacy practice, 2015-06, Vol.21 (3), p.170-177

2015

Volltextzugriff (PDF)

1 – 25 von 185

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(177)

Publikationsform

Artikel
(185)

Sprache

Englisch
(185)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(68)
Science & Technology
(68)
Humans
(55)
Oncology
(45)
Female
(38)
Middle Aged
(32)
Health Care Sciences & Services
(27)
Adult
(25)
Internal Medicine
(25)
Biological And Medical Sciences
(24)
Medical Sciences
(24)
Aged
(22)
Male
(20)
Breast Cancer
(18)
Cost-Benefit Analysis
(18)
Hematology, Oncology And Palliative Medicine
(18)
Chemotherapy
(17)
Pharmacology & Pharmacy
(16)
Cancer
(15)
Antineoplastic Agents - Adverse Effects
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

Clinical trial design in biosimilar drug development

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer

A Prospective Time and Motion Analysis Comparing Intravenous (IV) Vesus Subcutaneous (SC) Bortezomib in Patients with Multiple Myeloma (MM)

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

PSY4 Lenalidomide or Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma (MM): A Comparative Effectiveness Analysis Using Indirect Statistical Techniques

PCN6 Lenalidomide Versus Bortezomib for Treatment of Relapsed/Refractory Multiple Myeloma (MM): A Number Needed to Treat (NNT) Analysis

3602 POSTER The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Castration-Resistant Prostate Cancer (CRPC)

3603 POSTER The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Patients With Other Solid Tumours or Multiple Myeloma

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer

A Comparison of Toxicity and Supportive Care Use Between Four Cytotoxic Agents Used in the Management of Metastatic Breast Cancer (MBC)

1590 Patient-related factors in determining the emetic risk potential for patients undergoing chemotherapy: An evaluation of predictive models for the development of a risk assessment tool

PCN92 The Lifecycle Value of Oncology Medicines

PCN83 Novel Targeted Drug Therapies in the Cancer Setting: A Descriptive Comparison of Efficacy and Cost

PCN50 A Pilot Assessment to Determine Cost of Apheresis Treatment

What is a new drug worth? An innovative model for performance-based pricing

Small Molecule Targeted Therapies for the Second Line Treatment of Metastatic Renal Cell Carcinoma (mRCC): A Systematic Review and Indirect Comparison of Safety and Efficacy

Long-Acting Muscarinic Antagonists (Lama) In Chronic Obstructive Pulmonary Disease (Copd): A Rare Events Meta Analysis Of Clinically Relevant Adverse Events

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

Suchergebnisse filtern